The director of Pharmacy and Drugs of the Ministry of Health (Minsa), Elvia Lau, announced Monday that medicines containing the active ingredient ranitidine in all its pharmaceutical forms were withdrawn from the country.

The decision is made in compliance with Resolution 317 of August 11, 2022, which orders the preventive and immediate suspension of the health registration of all drugs that contain the active ingredient ranitidine.

“The manufacturers of the product had been told that they should show, based on evidence and quantitative analysis, whether or not the drug contained the impurity in considerable quantities and since they did not specify the demonstration, all its presentations were withdrawn. ”, stated Lau.

She likewise affirmed that the resolution also establishes that distribution agencies, importers, and manufacturers are ordered to withdraw all batches of medications in any of their formulations.